Find Beta-D-N4-hydroxycytidine manufacturers, exporters & distributors on PharmaCompass

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: N4-hydroxycytidine, Eidd-1931, Beta-d-n4-hydroxycytidine, N-hydroxycytidine, 3258-02-4, 4-n-hydroxycytidine

Molecular Formula

C₉H₁₃N₃O₆

Molecular Weight

259.22 g/mol

InChI Key

XCUAIINAJCDIPM-XVFCMESISA-N

FDA UNII

C3D11PV2O4

N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions. N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. It has shown antiviral activity against Venezuelan equine encephalitis virus, and the human coronavirus HCoV-NL63 in vitro. N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human airway epithelial cells. It is orally bioavailable in mice and distributes into tissue before becoming the active 5-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations. In non-human primates, N4-hydroxycytidine was poorly orally bioavailable. A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine. The prodrug of N4-hydroxycytidine, [EIDD-2801], is also being investigated for its broad spectrum activity against the coronavirus family of viruses.

1 2D Structure

Beta-D-N4-hydroxycytidine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hydroxyamino)pyrimidin-2-one

2.1.2 InChI

InChI=1S/C9H13N3O6/c13-3-4-6(14)7(15)8(18-4)12-2-1-5(11-17)10-9(12)16/h1-2,4,6-8,13-15,17H,3H2,(H,10,11,16)/t4-,6-,7-,8-/m1/s1

2.1.3 InChI Key

XCUAIINAJCDIPM-XVFCMESISA-N

2.1.4 Canonical SMILES

C1=CN(C(=O)N=C1NO)C2C(C(C(O2)CO)O)O

2.1.5 Isomeric SMILES

C1=CN(C(=O)N=C1NO)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O

2.2 Other Identifiers

2.2.1 UNII

C3D11PV2O4

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 4-oxime Uridine

2. Beta-d-n4-hydroxycytidine

3. Eidd-1931

4. N4-hydroxycytidine

2.3.2 Depositor-Supplied Synonyms

1. N4-hydroxycytidine

2. Eidd-1931

3. Beta-d-n4-hydroxycytidine

4. N-hydroxycytidine

5. 3258-02-4

6. 4-n-hydroxycytidine

7. C3d11pv2o4

8. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hydroxyamino)pyrimidin-2-one

9. 1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-(hydroxyimino)-3,4-dihydropyrimidin-2(1h)-one

10. 4-oxime Uridine

11. N-4-hydroxycytidine

12. Cytidine, N-hydroxy-

13. Ccris 1074

14. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-4-(hydroxyimino)-3,4-dihydropyrimidin-2(1h)-one

15. Unii-c3d11pv2o4

16. Eidd1931

17. Beta-d-n(4)-hydroxycytidine

18. N-hydroxy-3,4-dihydrocytidine

19. Schembl5190819

20. Chembl2178720

21. Eidd 1931

22. Gtpl10735

23. Dtxsid20186274

24. Chebi:180654

25. Ex-a3655

26. Mfcd01675695

27. At13085

28. Bs-47105

29. Hy-125033

30. Cs-0088698

31. 1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-(hydroxyamino)pyrimidin-2(1h)-one

32. 1-((2r,3r,4s,5r)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-4-hydroxyamino-1h-pyrimidin-2-one

33. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hydroxyamino)-1,2-dihydropyrimidin-2-one

34. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-4-(hydroxyamino)pyrimidin-2-one

2.4 Create Date

2005-08-01

3 Chemical and Physical Properties

Molecular Formula	C₉H₁₃N₃O₆
Molecular Weight	259.22 g/mol
XLogP3	-2.2
Hydrogen Bond Donor Count	5
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	3
Exact Mass	259.08043514 g/mol
Monoisotopic Mass	259.08043514 g/mol
Topological Polar Surface Area	135 Å²
Heavy Atom Count	18
Formal Charge	0
Complexity	398
Isotope Atom Count	0
Defined Atom Stereocenter Count	4
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

N4-hydroxycytidine and its prodrug [EIDD-2801] is being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2.

5 Pharmacology and Biochemistry

5.1 Absorption, Distribution and Excretion

Absorption

N4-hydroxycytidine is orally bioavailable in mice but poorly bioavailable in non-human primates.

5.2 Metabolism/Metabolites

N4-hydroxycytidine distributes into tissues where it is is phosphorylated to the 5'-triphosphate form.

5.3 Mechanism of Action

N4-hydroxycytidine is phosphorylated in tissue to the active 5-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations, known as viral error catastrophe. A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.

Drugs in Development